NEW YORK - (Business Wire) Viriathus Research LLC, an independent research firm, issued an Update Report today for Viralytics Limited (ASX: VLA) (OTC: VRACY), a biotechnology company that is developing therapies and drugs for the treatment of cancer in Australia. The report provides an update on Viralytics Limited’s business, industry, product, strategy, management team, and investment opportunities and risks.
The report is available free of charge at: http://www.viriathus.com/Research/VLA_AU_Viralytics_Ltd-Update_Report-November_2009.pdf
About Viriathus Research LLC
Viriathus Research is a quality-leading New York based independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutions that invest in them.
For further information on Viriathus Research, please visit www.viriathus.com/Research.htm
About Viralytics Limited
Viralytics is pioneering revolutionary new cancer therapies using oncolytic viruses to seek out and destroy cancer cells. Researchers have found that certain viruses have the capacity to preferentially target, infect and destroy cancer cells without causing excessive damage to surrounding normal tissue. The Company’s lead product CAVATAK™ is a form of Coxsackievirus A21 (CVA21), a naturally occurring common cold virus in human clinical trials, this virus has demonstrated bio-activity at low doses, rapid action, and has been well tolerated by patients. The preliminary human data support indications of anti-cancer activity of CAVATAK™ previously displayed in animal models.
For further information on Viralytics Limited, please visit www.viralytics.com.
Statement under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.
Viriathus Research LLC received $5,000 from the subject company in return for report authoring and distribution services.
Viriathus Research LLC
Lisa Springer, CFA
212-372-3116
lisa.springer@viriathus.com
www.viriathus.com
or
Viralytics Limited
Bryan Dulhunty, +61 2 9499 3200
Managing Director & CEO
www.viralytics.com
